Senores Pharma Q1 FY27: Revenue up 36%, EBITDA up 87% YoY
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharma reported strong Q1 FY27 results. Total revenue rose 36% YoY to about 180 crore rupees, driven by Regulated Markets (up 42% to about 128 crore) and Emerging Markets (up 30% to about 38 crore). EBITDA jumped 87% to about 54 crore with margin expansion of around 800 basis points. PAT grew 56% to about 31 crore. ANDA portfolio nearly doubled to 58 from 30 a year ago, with 23 commercialized. The Apnar USFDA facility is ramping up. Company guides for continued strong growth in FY27.
Strong beat across all metrics with broad-based growth, expanding margins, and upbeat FY27 guidance. Positive for sentiment.